secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2024-08-02T23:59:59+00:00
Accession:  0001628280-24-034481
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Ovid Therapeutics enters consulting agreement with departing General Counsel Thomas Perone
--------------------------------------------------------------------------------

- Thomas Perone departed as General Counsel, CCO and Corporate Secretary effective July 11, 2024, as part of a workforce reduction.
- Consulting agreement effective July 11, 2024 through January 31, 2025 to transition duties.
- Perone eligible for monthly consulting fee totaling up to $55,000 over the consulting period.
- Outstanding equity awards will continue to vest during the consulting period.
- Consulting agreement includes post-termination non-solicitation covenants through one year after termination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000162828024034481/0001628280-24-034481-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000162828024034481/ovid-20240730.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-034481

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer